We have located links that may give you full text access.
Optimizing management of tumor lysis syndrome in adults with hematologic malignancies.
Supportive Cancer Therapy 2005 April 2
Tumor lysis syndrome (TLS), caused by the release of cellular components into the blood after rapid cell lysis, is a serious problem in patients with hematologic malignancies. It is characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and secondary hypocalcemia, with serious clinical consequences including renal failure and death. Although TLS may occur spontaneously, it is more commonly caused by the destruction of malignant cells by chemotherapy. The risk of developing TLS is influenced by a number of characteristics including the type of malignancy, the type and intensity of anticancer treatment, and the presence of preexisting conditions such as renal insufficiency. Particularly, high-risk patients who have malignancies with a high rate of cell turnover are highly sensitive to chemotherapy. The identification and prophylactic treatment of patients at high risk of developing TLS is key to the management of TLS. This review provides a summary of the pathogenesis of TLS, risk factors for TLS, its associated incidence and clinical consequences, and pharmacologic options for prevention and treatment.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app